Heart disease is an umbrella term for multiple heart conditions, most commonly coronary artery disease. It remains a leading cause of death and includes conditions that may present with heart attack, arrhythmia, or heart failure events. Major modifiable risks include hypertension, high cholesterol, and smoking.
Anthropic announced it will run its own preclinical drug-discovery programs for neglected and rare diseases and launched Claude Science, an AI workbench for researchers. The company has not named specific diseases or detailed how it would bring candidates to market.
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
Alnylam Pharmaceuticals entered a $1.23 billion discovery collaboration with Tenaya Therapeutics to identify up to 15 novel genetic targets for heart disease. The agreement includes $10 million upfront and up to $1.13 billion in milestone payments.
More cancer survivors are living long enough to face lasting cardiovascular effects of treatment. Cardio-oncology clinics are managing heart failure, valvular disease and radiation-related heart disease.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Scientists at NTU Singapore developed an AI-powered biochip that detects multiple microRNA biomarkers in 20 minutes. The platform achieved more than 99 per cent accuracy in test channels.
The image-guided therapy systems market is expected to grow from US$4.96 billion in 2024 to US$8.42 billion by 2033 at a 6.05% CAGR. Growth is tied to minimally invasive care, chronic disease demand, and advances in imaging, AI, and navigation systems.
The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07591792 |
Outpatient Rehabilitation Programmes for Myocardial Ischemia, Heart Failure, and COPD: Satisfaction, Participation, Test Outcomes, and Factors Associated With Positive Changes in Test Results as Well as Level of Participation |
NOT_YET_RECRUITING | |
| NCT07558109 |
DigitHeart Echo Study |
RECRUITING | |
| NCT07502703 |
Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community |
NOT_YET_RECRUITING | |
| NCT07485738 |
The Relationship Between Blood Flow Readings During Surgery and How Well the Graft Stays Open and How Patients Recover Afterward in Coronary Artery Bypass Graft Surgery |
RECRUITING | NA |
| NCT07416279 |
Can Tiny Bubbles Offer an Alternative to Catheters for Assessing Pressures Inside the Heart? Investigating Ultrasound Contrast Agents as Pressure Sensors Against Gold Standard Catheter Pressures in Cardiac Catheterisation Patients. |
RECRUITING | NA |
| NCT07407816 |
Feasibility Study of the Supira System in Patients Undergoing HRPCI With Support Beyond the PCI Procedure |
RECRUITING | NA |
| NCT07388355 |
A Usability Study of a Multi-channel ECG Monitoring Device |
NOT_YET_RECRUITING | NA |
| NCT07380243 |
Pathways to Prevention Food-is-Medicine Trial |
RECRUITING | NA |
| NCT07378514 |
Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices |
NOT_YET_RECRUITING | |
| NCT07354347 |
Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD |
NOT_YET_RECRUITING | NA |
